Scholarlink

<p>Colorectal cancers (CRC) are the fourth most prevalent cancer in India. Treatment modalities range from surgery, chemotherapy, radiotherapy, targeted treatment, and immunotherapy, with surgery forming the cornerstone of curative treatment in combination with any of the above. We sought to explore the short-term surgical outcomes of curative colorectal resections from our center and compare them with the published outcomes elsewhere. This is a retrospective study of all colorectal cancers that underwent curative resections at our center, from 1st January 2017 to 31st October 2024. Patients were identified from a prospectively maintained surgical database and electronic medical records. The clinical, radiological, histopathological features, and 30-day surgical outcomes were evaluated. We identified 207 patients for the said duration, with the majority of them being males (60.9%, 126/207), left-sided tumors (70%, 145/207) and clinic-radiologically stage III cancers (66.2%, 137/207). Preoperative treatment was employed in 38.7% (80/207) patients who were mostly rectal primaries (78/80). A minimally invasive surgical (MIS) approach was attempted in 36 patients with a conversion rate of 16.7%. Extended resections were performed in 33 patients (15.9%). The median length of hospital stay was 7&#xa0;days (range 5 to 34&#xa0;days). We observed re-exploration rates of 7.2%, a readmission rate of 3.4%, major perioperative morbidity (Clavien-Dindo 3a or above) of 13%, and 30-day perioperative mortality of 2.9%. Margin-negative resections were achievable in almost all cases (99.5%, 206/207), and optimal nodal yield (12 or more) was attained in 90.8% (188/207). Our study provides preliminary evidence that safe colorectal resections, including extended resections, can be performed in low-volume and resource-constrained centers with acceptable perioperative morbidity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Short-Term Surgical Outcomes of Curative Colorectal Resections from an Evolving Low-Volume Cancer Center in a Tier-2 City in India

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月26日

查看全文
  • Vishnu S. Menon,
  • Amita Sekhar Padhy,
  • Rigved Nittala,
  • Mounika Basani,
  • Sidaksingh R. Arora

摘要

Colorectal cancers (CRC) are the fourth most prevalent cancer in India. Treatment modalities range from surgery, chemotherapy, radiotherapy, targeted treatment, and immunotherapy, with surgery forming the cornerstone of curative treatment in combination with any of the above. We sought to explore the short-term surgical outcomes of curative colorectal resections from our center and compare them with the published outcomes elsewhere. This is a retrospective study of all colorectal cancers that underwent curative resections at our center, from 1st January 2017 to 31st October 2024. Patients were identified from a prospectively maintained surgical database and electronic medical records. The clinical, radiological, histopathological features, and 30-day surgical outcomes were evaluated. We identified 207 patients for the said duration, with the majority of them being males (60.9%, 126/207), left-sided tumors (70%, 145/207) and clinic-radiologically stage III cancers (66.2%, 137/207). Preoperative treatment was employed in 38.7% (80/207) patients who were mostly rectal primaries (78/80). A minimally invasive surgical (MIS) approach was attempted in 36 patients with a conversion rate of 16.7%. Extended resections were performed in 33 patients (15.9%). The median length of hospital stay was 7 days (range 5 to 34 days). We observed re-exploration rates of 7.2%, a readmission rate of 3.4%, major perioperative morbidity (Clavien-Dindo 3a or above) of 13%, and 30-day perioperative mortality of 2.9%. Margin-negative resections were achievable in almost all cases (99.5%, 206/207), and optimal nodal yield (12 or more) was attained in 90.8% (188/207). Our study provides preliminary evidence that safe colorectal resections, including extended resections, can be performed in low-volume and resource-constrained centers with acceptable perioperative morbidity.